
 
 
 
 
 
 
 
 
   
 1. a kind of antibody or its antigen-binding fragment, the antibody or its antigen-binding fragment are with high-affinity combination people's MET egg
White (hMET) and with high-affinity combination mouse MET albumen (mMET), wherein the antibody or its antigen-binding fragment are
HMET agonist and mMET agonist. 
 
     
 
   
 
 2. antibody according to claim 1 or its antigen-binding fragment, wherein the antibody or its antigen-binding fragment packet
Containing at least one heavy chain variable domain (VH) and at least one light-chain variable domain (VL), wherein when the domain VH and VL is as Fab piece
When Duan Jinhang is tested, the VH and VL show 1 × 10 to hMET -3 s -1 To 1 × 10 -2 s -1 , optionally 1 × 10 -3 s -1 To 6 ×
10 -3 s -1 The dissociation rate (k measured by Biacore Dissociation ), and 1 × 10 is shown to mMET -3 s -1 To 1 × 10 -2 s -1 , appoint
Selection of land 1 × 10 -3 s -1 To 6 × 10 -3 s -1 The dissociation rate (k measured by Biacore Dissociation )。 
 
     
 
   
   
 
 3. antibody according to claim 1 or 2 or its antigen-binding fragment, wherein the antibody or its antigen binding fragment
Section has affinity of equal value to hMET and mMET. 
 
     
 
   
 
 4. antibody according to any one of the preceding claims or its antigen-binding fragment, wherein the antibody or it is anti-
The phosphorylation of former binding fragment induction hMET, and induce the phosphorylation of mMET. 
 
     
 
   
 
 5. antibody according to claim 4 or its antigen-binding fragment, wherein the antibody or antigen-binding fragment are with small
In the EC of 3.0nM, optionally less than 2.0nM 50 The phosphorylation of (being measured by phosphorylation MET ELISA) induction hMET, and with
Less than the EC of 3.0nM, optionally less than 2.0nM 50 The phosphorylation of (being measured by phosphorylation MET ELISA) induction mMET. 
 
     
 
   
   
 
 6. antibody according to claim 4 or 5 or its antigen-binding fragment, wherein the antibody or its antigen binding fragment
Section equivalently induces the phosphorylation of hMET and mMET. 
 
     
 
   
   
   
 
 7. the antibody according to claim 4 to 6 or its antigen-binding fragment, wherein the antibody or its antigen binding fragment
Section shows high phosphorylation effect to hMET, and high phosphorylation effect is shown to mMET. 
 
     
 
   
 
 8. antibody according to claim 7 or its antigen-binding fragment, wherein the antibody or its antigen-binding fragment with
EC less than 1nM 50 And/or at least 80% E max (being indicated with the percentage of HGF induced activation in phosphorylation MET ELISA) lures
The phosphorylation of hMET is led, and to be less than the EC of 1nM 50 And/or at least 80% E max It (is lured with HGF in phosphorylation MET ELISA
Lead activation percentage indicate) induction mMET phosphorylation. 
 
     
 
   
   
   
   
   
   
 
 9. according to claim 1 to antibody described in 6 or its antigen-binding fragment, wherein the antibody or its antigen binding fragment
Section shows low phosphorylation effect to hMET, and low phosphorylation effect is shown to mMET. 
 
     
 
   
 
 10. antibody according to claim 9 or its antigen-binding fragment, wherein the antibody or its antigen-binding fragment
With the EC of 1nM~5nM 50 And/or 60~80% E max (being indicated with the percentage of HGF induced activation in phosphorylation MET ELISA)
The phosphorylation of hMET is induced, and with the EC of 1nM~5nM 50 And/or 60~80% E max (with HGF in phosphorylation MET ELISA
The percentage of induced activation indicates) phosphorylation of induction mMET. 
 
     
 
   
 
 11. antibody according to any one of the preceding claims or its antigen-binding fragment, wherein the antibody or it is anti-
Former binding fragment induces HGF like cell response when contacting with people's cell, and induces HGF sample thin when contacting with mouse cell
Born of the same parents' response. 
 
     
 
   
 
 12. antibody according to claim 11 or its antigen-binding fragment, wherein the antibody or its antigen-binding fragment
Induce the response of HGF like cell completely when contacting with people's cell and when contacting with mouse cell. 
 
     
 
   
   
 
 13. antibody according to claim 11 or 12 or its antigen-binding fragment, wherein HGF like cell response it is complete
Induction is measurable when there are both one of following, any or the whole circumstances: 
 (i) described anti-when the concentration of the antibody or its antigen-binding fragment is 0.1~1.0nM in cell decentralized detection
Body or the induction of its antigen-binding fragment and the comparable cell of dispersion of maximum HGF induction disperse； 
 (ii) in anti-apoptotic cell detection, the antibody or its antigen-binding fragment show EC 50 EC less than HGF 50 1.1
Times and/or E max (being measured with the % of total ATP content of non-apoptosis control cell) is greater than the E observed to HGF max 90%；
And/or 
 (iii) occur in detection in branching form, gone out with the cells show that the antibody is handled each dense by identical (non-zero)
The orbicule of the HGF induction of degree is greater than 90% branch amount. 
 
     
 
   
 
 14. antibody according to claim 11 or its antigen-binding fragment, wherein the antibody or its antigen-binding fragment
The part induction HGF like cell response when being contacted with people's cell and when being contacted with mouse cell. 
 
     
 
   
 
 15. antibody according to claim 14 or its antigen-binding fragment, wherein the part of HGF like cell response induces
It is measurable when there is the case where following (i)-(iii): 
 (i) in cell decentralized detection, when the concentration of the antibody is 1nM or lower, the antibody or its antigen binding fragment
The cell dispersion of section induction is by least the 25% of the cell dispersion of the homologous HGF induction of 0.1nM； 
 (ii) in anti-apoptotic cell detection, the antibody or its antigen-binding fragment show EC 50 EC no more than HGF 50 's
7.0 times and/or E max Cell survival rate is the E observed to HGF max At least the 50% of cell survival rate；And/or 
 (iii) occur in detection in branching form, gone out with the cells show that the antibody is handled each dense by identical (non-zero)
The branch amount of the orbicule at least 25% of the HGF induction of degree； 
 And the antibody or antigen-binding fragment not exclusively induce HGF like cell response. 
 
     
 
   
 
 16. antibody according to any one of the preceding claims or its antigen-binding fragment, wherein the antibody or it is anti-
Former binding fragment is HGF competitor. 
 
     
 
   
 
 17. antibody according to claim 16 or its antigen-binding fragment, wherein the antibody or its antigen-binding fragment
To be not more than the IC of 5nM 50 And/or at least 50% I max With hHGF competitive binding hMET, and be not more than 5nM IC 50 With/
Or at least 50% I max With mHGF competitive binding mMET. 
 
     
 
   
   
 
 18. antibody according to claim 16 or 17 or its antigen-binding fragment, wherein the antibody or its antigen binding
Segment is equivalently competed with hHGF and mHGF. 
 
     
 
   
   
   
 
 19. antibody described in any one of 6 to 18 or its antigen-binding fragment according to claim 1, wherein the antibody or its
Antigen-binding fragment is complete HGF competitor. 
 
     
 
   
 
 20. antibody according to claim 19 or its antigen-binding fragment, wherein the antibody or its antigen-binding fragment
To be less than the IC of 2nM 50 And/or the I greater than 90% max It is competed with hHGF, and to be less than the IC of 2nM 50 And/or greater than 90%
I max It is competed with mHGF. 
 
     
 
   
   
   
 
 21. antibody described in 6 to 18 or its antigen-binding fragment according to claim 1, wherein the antibody or its antigen binding
Segment is part HGF competitor. 
 
     
 
   
 
 22. antibody according to claim 21 or its antigen-binding fragment, wherein the antibody or its antigen-binding fragment
With the IC of 2~5nM 50 And/or 50%~90% I max It is competed with hHGF, and with the IC of 2~5nM 50 And/or 50%~90%
I max It is competed with mHGF. 
 
     
 23. a kind of antibody or its antigen-binding fragment, the antibody or the identification of its antigen-binding fragment are located at the 123rd of people MET
Amino acids residue to the 223rd residue, people MET the 224th amino acids residue to the 311st residue, people MET the 314th
The epitope of people MET of the position residue to the 546th residue of the 372nd residue or people MET into the region of the 562nd residue. 
 
     
 24. the table in the extracellular domain of a kind of antibody or its antigen-binding fragment, the antibody or its antigen-binding fragment identification MET
Position, the extracellular domain of the MET include the one or more amino acid guarded in people and mouse MET. 
 
     
 25. a kind of antibody or its antigen-binding fragment, the epitope of the antibody or its antigen-binding fragment identification people MET is described
The epitope of people MET includes the amino acid residue Ile367 and/or Asp372 of people MET, and optionally wherein, the epitope is located at people
The 314th amino acids residue of MET is into the region of the 372nd residue. 
 
     
 26. a kind of antibody or its antigen-binding fragment, the epitope of the antibody or its antigen-binding fragment identification people MET is described
The epitope of people MET includes the amino acid residue Thr555 of people MET, and optionally wherein, the epitope is located at the 546th of people MET
Amino acid residue is into the region of the 562nd residue. 
 
     
 27. a kind of antibody or its antigen-binding fragment, the antibody or its antigen-binding fragment include heavy chain variable domain and light chain
Variable domain, the heavy chain variable domain include H-CDR1, H-CDR2 and H-CDR3, and the light-chain variable domain includes L-CDR1, L-
CDR2 and L-CDR3, in which: 
 H-CDR1 includes the amino acid sequence selected from SEQ ID NO:2,9,16,23,30,37,44,51,58,65 and 72； 
 H-CDR2 includes the amino acid sequence selected from SEQ ID NO:4,11,18,25,32,39,46,53,60,67 and 74； 
 H-CDR3 includes the amino acid sequence selected from SEQ ID NO:6,13,20,27,34,41,48,55,62,69 and 76； 
 L-CDR1 includes the amino acid selected from SEQ ID NO:79,86,93,100,107,114,121,128,135,142 and 149
Sequence； 
 L-CDR2 includes the amino acid selected from SEQ ID NO:81,88,95,102,109,116,123,130,137,144 and 151
Sequence；And 
 L-CDR3 includes the amino acid selected from SEQ ID NO:83,90,97,104,111,118,125,132,139,146 and 153
Sequence. 
 
     
 
   
   
   
   
   
 
 28. the antibody according to any one of claim 23 to 27 is according to claim 1 to described in any one of 22
Antibody or antigen-binding fragment. 
 
     
 A kind of [29. 71G2] antibody or antigen-binding fragment, it includes heavy chain variable domain and light-chain variable domain, the weight chain variable
Domain includes H-CDR1, H-CDR2 and H-CDR3, and the light-chain variable domain includes L-CDR1, L-CDR2 and L-CDR3, in which: 
 H-CDR1 includes amino acid sequence shown in SEQ ID NO:44； 
 H-CDR2 includes amino acid sequence shown in SEQ ID NO:46； 
 H-CDR3 includes amino acid sequence shown in SEQ ID NO:48； 
 L-CDR1 includes amino acid sequence shown in SEQ ID NO:121； 
 L-CDR2 includes amino acid sequence shown in SEQ ID NO:123；And 
 L-CDR3 includes amino acid sequence shown in SEQ ID NO:125. 
 
     
 
   
 
 [30. 71G2] antibody according to claim 23 or antigen-binding fragment, wherein the heavy chain variable domain includes
The amino acid sequence of SEQ ID NO:167, or with the amino acid sequence at least 90%, 95%, 97% of SEQ ID NO:167 or
The sequence of 99% identity；And the light-chain variable domain include SEQ ID NO:168 amino acid sequence, or with SEQ ID
The sequence of the amino acid sequence of NO:168 at least 90%, 95%, 97% or 99% identity. 
 
     
 
   
   
 
 It is according to claim 1 to any in 22 31. the antibody according to claim 29 or 30 or antigen-binding fragment
Antibody or antigen-binding fragment described in. 
 
     
 A kind of [32. 71D6] antibody or antigen-binding fragment, it includes heavy chain variable domain and light-chain variable domain, the weight chain variable
Domain includes H-CDR1, H-CDR2 and H-CDR3, and the light-chain variable domain includes L-CDR1, L-CDR2 and L-CDR3, in which: 
 H-CDR1 includes amino acid sequence shown in SEQ ID NO:30； 
 H-CDR2 includes amino acid sequence shown in SEQ ID NO:32； 
 H-CDR3 includes amino acid sequence shown in SEQ ID NO:34； 
 L-CDR1 includes amino acid sequence shown in SEQ ID NO:107； 
 L-CDR2 includes amino acid sequence shown in SEQ ID NO:109；And 
 L-CDR3 includes amino acid sequence shown in SEQ ID NO:111. 
 
     
 
   
 
 [33. 71D6] antibody according to claim 25 or antigen-binding fragment, wherein the heavy chain variable domain includes
The amino acid sequence of SEQ ID NO:163, or with the amino acid sequence at least 90%, 95%, 97% of SEQ ID NO:163 or
The sequence of 99% identity；And the light-chain variable domain include SEQ ID NO:164 amino acid sequence, or with SEQ ID
The sequence of the amino acid sequence of NO:164 at least 90%, 95%, 97% or 99% identity. 
 
     
 
   
   
 
 It is according to claim 1 to any in 22 34. the antibody according to claim 32 or 33 or antigen-binding fragment
Antibody or antigen-binding fragment described in. 
 
     
 A kind of [35. 71G3] antibody or antigen-binding fragment, it includes heavy chain variable domain and light-chain variable domain, the weight chain variable
Domain includes H-CDR1, H-CDR2 and H-CDR3, and the light-chain variable domain includes L-CDR1, L-CDR2 and L-CDR3, in which: 
 H-CDR1 includes amino acid sequence shown in SEQ ID NO:9； 
 H-CDR2 includes amino acid sequence shown in SEQ ID NO:11； 
 H-CDR3 includes amino acid sequence shown in SEQ ID NO:13； 
 L-CDR1 includes amino acid sequence shown in SEQ ID NO:86； 
 L-CDR2 includes amino acid sequence shown in SEQ ID NO:88；And 
 L-CDR3 includes amino acid sequence shown in SEQ ID NO:90. 
 
     
 
   
 
 [36. 71G3] antibody according to claim 27 or antigen-binding fragment, wherein the heavy chain variable domain includes
The amino acid sequence of SEQ ID NO:157, or with the amino acid sequence at least 90%, 95%, 97% of SEQ ID NO:157 or
The sequence of 99% identity；And the light-chain variable domain include SEQ ID NO:158 amino acid sequence, or with SEQ ID
The sequence of the amino acid sequence of NO:158 at least 90%, 95%, 97% or 99% identity. 
 
     
 
   
   
 
 It is according to claim 1 to any in 22 37. the antibody according to claim 35 or 36 or antigen-binding fragment
Antibody or antigen-binding fragment described in. 
 
     
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 38. one kind is according to claim 1 to the affine variant or ethnic group of antibody or antigen-binding fragment described in any one of 37
It is variant. 
 
     
 
   
 
 39. antibody according to any one of the preceding claims or antigen-binding fragment, the hinge area containing human IgG,
The domain CH2 and/or the domain CH3, the optionally hinge area of IgG1, the domain CH2 and/or the domain CH3. 
 
     
 
   
 
 40. antibody according to any one of the preceding claims, it includes have with human IgG, preferably IgG1 at least 90%,
95%, the domain CH2 and/or CH3 of the sequence of 97% or 99% identity, optionally wherein, the domain CH2 and/or CH3 are repaired
It is decorated with reduction or substantially eliminates one or more antibody mediated effect functions. 
 
     
 
   
 
 41. antibody according to any one of the preceding claims or antigen-binding fragment, wherein the domain VH and/or VL or
One or more CDR are derived from camellid. 
 
     
 
   
 
 42. antibody according to claim 41 or antigen-binding fragment, wherein the animal is llama. 
 
     
 43. a kind of isolated polynucleotides, the isolated polynucleotide encoding is according to claim 1 to described in any one of 42
Antibody or antigen-binding fragment. 
 
     
 44. a kind of expression vector, the expression vector includes to be operably connected with adjusting sequence according to claim 43 institute
The polynucleotides stated, the adjusting sequence allow the antibody or its antigen-binding fragment in host cell or cell-free expression system
It is expressed in system. 
 
     
 45. a kind of host cell or Cell free expression system, the host cell or Cell free expression system contain with good grounds right
It is required that expression vector described in 43. 
 
     
 46. a kind of method for producing recombinant antibodies or its antigen-binding fragment, the method includes allowing to express the antibody
Or host cell or Cell free expression system according to claim 45 are cultivated under conditions of antigen-binding fragment and is returned
Receive the antibody or antigen-binding fragment of expression. 
 
     
 47. a kind of pharmaceutical composition, described pharmaceutical composition include according to claim 1 to antibody described in any one of 42 or
Antigen-binding fragment and at least one pharmaceutically acceptable carrier or excipient. 
 
     
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 48. according to claim 1 to antibody or antigen-binding fragment described in any one of 42 or according to claim 47
Pharmaceutical composition application in the treatment. 
 
     
 49. a kind of method for treating or preventing human patient hepatic injury, the hepatic injury is optionally acute liver damage or Chronic Liver damage
Wound, the method includes the MET agonist antibodies to patient's dosage treatment effective amount in need. 
 
     
 
   
 
 50. according to the method for claim 49, wherein the MET agonist antibody is to appoint according to claim 1 in 42
Antibody or antigen-binding fragment described in one. 
 
     
 51. a kind of method for treating or preventing human patient injury of kidney, the injury of kidney is optionally acute kidney injury, the method packet
Include the MET agonist antibody to patient's dosage treatment effective amount in need. 
 
     
 
   
 
 52. method according to claim 51, wherein the MET agonist antibody is to appoint according to claim 1 in 42
Antibody or antigen-binding fragment described in one. 
 
     
 53. a kind of method for treating or preventing human patient inflammatory bowel disease, the inflammatory bowel disease is optionally ulcerative colitis, described
Method includes the MET agonist antibody to patient's dosage treatment effective amount in need. 
 
     
 
   
 
 54. method according to claim 53, wherein the MET agonist antibody is to appoint according to claim 1 in 42
Antibody or antigen-binding fragment described in one. 
 
     
 55. a kind of method for treating or preventing human patient diabetes, the diabetes are optionally type-1 diabetes mellitus or II type glycosuria
Disease, the method includes the MET agonist antibodies to patient's dosage treatment effective amount in need. 
 
     
 
   
 
 56. method according to claim 55, wherein the MET agonist antibody is to appoint according to claim 1 in 42
Antibody or antigen-binding fragment described in one. 
 
     
 57. a kind of method for treating or preventing human patient nonalcoholic fatty liver disease, the method includes to trouble in need
The MET agonist antibody of person's dosage treatment effective amount. 
 
     
 
   
 
 58. method according to claim 57, wherein the MET agonist antibody is to appoint according to claim 1 in 42
Antibody or antigen-binding fragment described in one. 
 
     
 59. a kind of method for the treatment of or promotion human patient wound healing, the human patient is optionally to suffer from the patient of diabetes, institute
The method of stating includes the MET agonist antibody to patient's dosage treatment effective amount in need. 
 
     
 
   
 
 60. method according to claim 59, wherein the MET agonist antibody is to appoint according to claim 1 in 42
Antibody or antigen-binding fragment described in one. 
 
   
 
 
 
 
 
 
 
 
